COVID-19与慢阻肺
慢阻肺患者罹患COVID-19时重症肺炎和不良结局风险增加,可能与肺储备功能差或小气道ACE-2受体表达增加有关。但估计慢阻肺患者感染及重症风险面临挑战,因病例报告集中于住院和ICU患者,且全球检测策略差异大。
要点
- 慢阻肺患者感染COVID-19后重症肺炎和不良结局风险增加。
- 机制可能与肺储备功能差或小气道ACE-2受体表达增加有关。
- 疫情早期病例报告偏重住院和ICU患者,轻症门诊病例报告不足。
核心结论
- 慢阻肺患者罹患COVID-19时发生重症肺炎和不良结局的风险增加。
主要发现
- 慢阻肺患者的重症风险可能与肺储备功能差或小气道ACE-2受体表达增加有关。
- 病例报告集中于住院和ICU患者,而非轻症门诊病例,部分因全球检测策略差异。
局限性
- 病例报告集中于住院和ICU患者,轻症门诊病例报告不足。
- 全球检测策略差异大,部分国家仅检测需住院者,影响风险估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COPD patients have increased risk of severe pneumonia and poor outcomes when they develop COVID-19. This may be related to poor underlying lung reserves or increased expression of ACE-2 receptor in small airways. https://bit.ly/37dSB8l As of 11 July, 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic has infected over 12.7 million people around the world and caused more than 560,000 deaths [1]. Given the devastating impact that COVID-19 can have on the lung, it is natural to fear for patients with underlying COPD. Estimating their excess risk for contracting COVID-19 and, in particular, its more severe respiratory manifestations has been a challenging exercise in this pandemic for various reasons. First, the reporting on cases has concentrated on hospitalised and intensive care unit (ICU) patients, rather than on mild, outpatient cases. This is in part also due to the variability in testing strategies across the world, where some nations with stricter testing requirements and scarce testing resources have focused on testing only those requiring hospitalisation.
引用
- Leung JM, Niikura M, Yang CWT, et al. COVID-19 and COPD. Eur Respir J. 2020. PMID: 32817205. doi:10.1183/13993003.02108-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。